Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Thursday Nov 25, 2021
Thursday Nov 25, 2021
touchEXPERT OPINIONS for touchOPHTHALMOLOGY
Listen to expert insights on how novel IOLs can address patients’ visual needs, the factors that influence IOL selection and managing patient expectations.
The expert
- Dr Rosa Braga-Mele - Professor of Ophthalmology, Faculty of Medicine at the University of Toronto, Canada.
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Alcon Laboratories Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchophthalmologyime.org/balancing-risks-and-benefits-of-intraocular-lens-options-for-cataract-surgery/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen as leading experts discuss the latest clinical data for emerging HER2-directed therapies and review novel therapeutic strategies and consider the implications for clinical practice.
The experts
- Dr Laura Biganzoli – Department of Oncology, Hospital of Prato, Prato, Italy
- Dr Peter Fasching – Comprehensive Cancer Center, Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
- Dr Sonia Pernas – Catalan Institute of Oncology, and Faculty of Medicine, University of Barcelona, Barcelona, Spain
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from SeaGen. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/expanding_options_her2_advanced_breast_cancer/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist, a pathologist, a radiation oncologist and an oncology nurse practitioner discuss how to optimize treatment decisions, taking into account emerging therapies as well as patient expectations and preferences.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
- Radiation oncologist: Prof. Andrea Bezjak, Canada
- Oncology nurse practitioner: Dr Marianne Davies, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a pathologist discuss the evolving role of biomarker testing in NSCLC in the light of emerging testing methodologies and treatment targets.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
Listen to a medical oncologist, a pathologist and an oncology nurse practitioner discuss the evolving treatment landscape and how treatment decisions need to take into account potential side effects.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
- Oncology nurse practitioner: Dr Marianne Davies, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a radiation oncologist discuss the importance of the initial assessment in NSCLC and the role of the different members of the multidisciplinary team.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Radiation oncologist: Prof. Andrea Bejzak, Canada
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Friday Nov 05, 2021
Friday Nov 05, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen to leading experts review the latest advances in HR+ breast cancer, focusing on the management of specific patient subgroups and the potential impact of emerging oral, second-generation SERDs on patient standard of care.
The experts
- Prof. Hope S Rugo – UCSF Comprehensive Cancer Center, San Francisco, CA, USA
- Dr Fatima Cardoso – Champalimaud Clinical Center, Lisbon, Portugal
- Dr Matti Aapro – Genolier Cancer Center, Genolier, Switzerland
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from Sanofi Genzyme. This activity is provided by touchIME.
For further information visit our website: https://touchoncologyime.org/emerging-serds-for-treating-hr-positive-breast-cancer/
Tuesday Oct 26, 2021
Tuesday Oct 26, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.
The experts
- Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland
- Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/
Monday Oct 25, 2021
Monday Oct 25, 2021
touchPANEL DISCUSSION for touchENDOCRINOLOGY
Listen to leading experts discuss why the treatment landscape for patients with T2D and CKD requires novel therapies; why non-steroidal MRAs are being investigated in these patients and the latest clinical data; and how non-steroidal MRAs might fit into the current T2D and CKD treatment paradigm.
The experts
- Prof. Christoph Wanner, University Hospital of Würzburg, Würzburg, Germany
- Dr Javed Butler, University of Mississippi Medical Center, Jackson, MS, USA
- Prof. Janet McGill, Washington University School of Medicine, St. Louis, MO, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from Bayer. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchendocrinologyime.org/non-steroidal-mras-in-the-management-of-patients-with-ckd-and-t2d
Monday Oct 18, 2021
Monday Oct 18, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen to leading experts discuss evolving treatment options for patients with EGFR-mutant NSCLC, and the rationale for biomarker testing in both early-stage and metastatic disease to determine best treatment approaches, taking in recently presented data from the World Lung Cancer Congress and ESMO Congress 2021.
The experts
- Dr Pasi Jӓnne, Dana-Farber Cancer Institute, Boston, MA, USA
- Dr Thanyanan Reungwetwattana, Ramathibodi Hospital, Bangkok, Thailand
- Dr Neal Navani, University College London, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/deciphering-data-egfr-mutant-nsclc/